ClinicalTrials.gg
CompletedNCT07019909Updated Feb 25, 2026

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults

A Phase 1 interventional study of 20vPnC and 13vPnC in Pneumococcal Disease, sponsored by Pfizer. Completed at 3 sites in China. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Pfizer · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
14th of 19
400 · median 668
Started
2025
with 1 other
Phase 1
3 of 19
1 open now
Registered
16th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 14th largest by enrollment, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 16th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This Phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in China. The purpose of the study is to learn about the safety and immune response of 20vPnC and 13vPnC in Chinese adults 50 years of age and older who did not receive any of pneumococcal vaccine in the past

Read the detailed description

The purpose of the study is to learn about the safety and immune response of 20vPnC and 13vPnC vaccines in Chinese adults. This study is seeking for participants who:

  • are 50 years of age and older
  • did not receive any of vaccines used to treat infections caused by the bacteria called Streptococcus pneumonia in the past.

The participants will be grouped by three age groups:

  • Adults between 50 to 59 years of age
  • Adults between 60 to 64 years of age
  • Adults who are 65 years of age or above

All participants in this study will receive a single dose of 20vPnC or 13vPnC at study clinic. The study will look at the experiences of people receiving 20vPnC and 13vPnC. This will help decide if the study vaccine is safe.

The total duration of taking part in the study will be around 6 months, with 6 visits.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key inclusion criteria:

1.Generally healthy adults including those with preexisting stable disease determined to be eligible based on clinical assessment, medical history and clinical judgment.

Key exclusion criteria:

  1. History of microbiologically-proven invasive disease caused by Streptococcus pneumoniae
  2. Previous vaccination with any licensed or pneumococcal vaccine or planned receipt through study participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    20vPnC

    Single dose of 20-valent pneumococcal conjugate vaccine

    Biological: 20vPnC

  • Experimental
    13vPnC

    Single dose of 13-valent pneumococcal conjugate vaccine

    Biological: 13vPnC

Interventions

  • Biological20vPnC

    20 valent pneumococcal conjugate vaccine

  • Biological13vPnC

    13 valent pneumococcal conjugate vaccine

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting prompted local reactions within 7 days following investigational product administration

    Prespecified local reactions (redness, swelling, and pain at the injection site)

    Time frame: Within 7 days after vaccination

  2. Percentage of participants reporting prompted systemic events within 7 days following investigational product administration

    Prespecified systemic events (fever, headache, fatigue, muscle pain, and joint pain)

    Time frame: Within 7 days after vaccination

  3. Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration

    Adverse events occurring within 1 month after vaccination

    Time frame: Within 1 month after vaccination

  4. Percentage of participants reporting serious adverse events (SAEs) throughout the study

    SAEs occurring within 6 months after vaccination

    Time frame: Within 6 months after vaccination

  5. Percentage of participants reporting abnormal hematology, biochemistry, and urinalysis and microscopy laboratory values

    Abnormal hematology, biochemistry, and urinalysis and microscopy laboratory values

    Time frame: 3 to 5 days after vaccination

Secondary outcomes

  1. Pneumococcal serotype-specific Opsonophagocytic activity (OPA) geometric mean titer (GMT)

    Pneumococcal serotype-specific OPA GMTs

    Time frame: 1 month after vaccination

  2. Pneumococcal serotype-specific OPA geometric mean fold rise (GMFR)

    Pneumococcal serotype-specific OPA GMFRs

    Time frame: Before vaccination to 1 month after vaccination

07

Study locations

3 sites
  • Zhejiang provincial center for disease control and prevention
    Hangzhou, Zhejiang 310051, China
  • Kaihua County Center For Disease Prevention and Control
    Kaihua, Zhejiang 324300, China
  • Kaihua County Center For Disease Prevention and Control
    Quzhou, Zhejiang 324300, China
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jan 2026, 6 months.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Jul 6, 2025
Primary completionActual
Jan 28, 2026
CompletionActual
Jan 28, 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019909
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jul 6, 2025
Primary completion
Jan 28, 2026
Completion
Jan 28, 2026
Last update
Feb 25, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pneumococcal 20-Valent Conjugate Vaccine · 13-valent pneumococcal vaccine

Start the discussion